HHS Cannabis Rescheduling Recommendation Announcement Anticipated Soon
In a recent email from the US Department of Justice addressing the ongoing lawsuit surrounding the Freedom of Information Act (FOIA) redaction of the Health and Human Services (HHS) letter to the Drug Enforcement Administration (DEA), significant developments are on the horizon.
The email, responding to a motion for summary judgment, conveyed that the agency is set to release the letter and its enclosures in their entirety.
The recipient of the email, Matt Zorn, downplayed the significance, stating, “This is nothing to me. Impossible just takes a few weeks. I do this in my sleep. This could mean, by the way, that a rescheduling is imminent—or not.”
As the anticipation builds, legal experts weigh in on the potential timing and manner of the release. A lawyer closely observing the situation commented, “HHS could release as part of the publication of the DEA proposed rule, or it could release independently. My guess is (and it’s a guess) that it will be released with the proposed rule, but we’ll see.”
Adding to the speculation, the same legal observer remarked, “The release of the unredacted HHS recommendation and evaluation—all parts of it—is coming imminently. If that release occurs as part of DEA publishing its proposed rule in the Federal Register, then the proposed rule is also coming imminently. We don’t know at the moment which it is.”
The unfolding developments have heightened interest in the potential impact of the rescheduling decision on various stakeholders. The email from the Department of Justice suggests that the motion for summary judgment will become moot once the agency releases the complete letter, implying a pivotal moment in the ongoing legal battle.
While Zorn maintains a nonchalant stance, the broader industry eagerly awaits clarity on whether a rescheduling of substances is indeed on the horizon. The intricate interplay between the HHS recommendation, the DEA proposed rule, and the imminent release has created an atmosphere of uncertainty, leaving industry participants and legal experts alike on the edge of their seats.
Information for this briefing was found via the sources mentioned. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.
Who really cares, yawn…